Showing results (151-160 of 185) with videos related to
Sort By:
Pageof 19
Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapyS Shinkaruk, M Bayle, G Laïn, et al.Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studiesEdward A SausvilleCurrent Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Implication of raft microdomains in drug induced apoptosisChristine Bezombes, Guy Laurent, Jean-Pierre JaffrézouCurrent Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Apoptosis induced by topoisomerase inhibitorsOlivier Sordet, Qasim A Khan, Kurt W Kohn, et al.Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Signal transduction pathways of taxanes-induced apoptosisValérie Ganansia-Leymarie, Pierre Bischoff, Jean-Pierre Bergerat, et al.Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Drugs acting on the beta isoform of human topoisomerase II (p180)B Gatto, E LeoCurrent Medicinal Chemistry. Anti-Cancer Agents|July 23, 2003
Death receptor ligands: new strategies for combined treatment with ionizing radiationPatrizia Marini, Claus BelkaCurrent Medicinal Chemistry. Anti-Cancer Agents|July 23, 2003
New targets for the modulation of radiation response--selective inhibition of the enzyme cyclooxygenase 2Cordula Petersen, Michael Baumann, Sven PetersenCurrent Medicinal Chemistry. Anti-Cancer Agents|July 23, 2003
Radioprotection of normal tissue to improve radiotherapy: the effect of the Bowman Birk protease inhibitorK H Dittmann, C Mayer, H P RodemannCurrent Medicinal Chemistry. Anti-Cancer Agents|July 23, 2003
Antiangiogenesis and radiotherapy: what is the role of combined modality treatment?Johannes Classen, Wilfried BudachPageof 19